Follow-up data suggest a survival advantage over current standard treatments, with some patients surviving over 30 months, including long-term responders surviving up to 38.3 months.

Survival data from this cohort significantly outperform benchmarks from similar studies, where one-year survival rates typically range from 23% to 40%.

A Phase 2 clinical trial of Bria-IMT combined with checkpoint inhibitors has demonstrated promising survival benefits in heavily pretreated metastatic breast cancer patients, with a 52% one-year survival rate among 25 patients and some surviving over 30 months.

Expert commentary highlights the significance of these survival data, especially given the difficult-to-treat patient population, and emphasizes the potential of Bria-IMT to improve outcomes for late-stage metastatic breast cancer.

BriaCell's promising Phase 2 results surpass current standard care expectations, with a survival rate that indicates potential for meaningful clinical impact.

Despite these promising results, BriaCell is operating with negative cash flow, burning through $3.36 million in the last year, making upcoming trial outcomes crucial for its future prospects.

The trial's treatment schedule involves three-week cycles of therapies including cyclophosphamide, SV-BR-1-GM, checkpoint inhibitors, and interferon, with imaging assessments every 6 to 8 weeks.

BriaCell's ongoing Phase 3 trial has expanded to 58 sites across 15 states, with patient enrollment expected to conclude by early 2026 and top-line results anticipated in the first half of that year.

The encouraging results from these studies bolster confidence in BriaCell’s potential to improve outcomes for patients with advanced disease, including ongoing and future trials.

A Phase 3 pivotal trial (NCT06072612) is underway to provide more definitive efficacy data in metastatic breast cancer using the same formulation.

Patients in the study had failed multiple prior therapies, including checkpoint inhibitors and antibody-drug conjugates, with a median of six previous treatments, yet no treatment discontinuations related to Bria-IMT were reported.

The ongoing Phase 3 trial (BRIA-ABC) compares Bria-IMT plus Retifanlimab against physician’s choice treatments, enrolling up to 404 participants to further evaluate efficacy.

Bria-IMT has shown a favorable safety profile, with no treatment-related discontinuations, even in patients with advanced disease.